
Recently Approved Drug Ultomiris Performs Well in Atypical Hemolytic Uremic Syndrome Trial
According to a story from statnews.com, the biotechnology company Alexion Pharmaceuticals recently announced that its product Ultomiris, which was recently approved as a treatment for paroxysmal nocturnal hemoglobinuria, was also…